Join Growin Stock Community!

Humana inc(HUM.US AI Earnings Summary)

US StockHealthcare
No presentation for HUM

HUM AI Earnings Summary (In-Depth)

Last updated: 2026-11-06 (US time)

2026 Q3

Core Highlights

Operations demonstrate strong recovery momentum, with full-year earnings guidance raised driven by better-than-expected medical cost control.

  • Stock Price Reaction: Results were released before the U.S. market open on 11/6. Supported by a Q3 adjusted loss per share of $0.70 (better than the expected $1.00 loss), stellar Medical Loss Ratio (MLR) performance, and the raised full-year profit outlook, the stock closed at $433.74 on 11/6 (the first trading day after earnings), up 5.33% from the 11/5 close of $411.79.
  • Against Market Expectations: Adjusted loss per share for the quarter was $0.70, better than the $1.00 loss TradingView pre-earnings market expectation (a $0.30 beat); revenue of $41.155B was about 0.7% above the $40.873B market expectation.
  • Against Previous Guidance: Full-year medical cost trends landed at the lower end of the 7%–8% expected range, consistent with guidance; the expected gain of approximately $900M from the sale of a minority stake in Gentiva is also on track. Benefiting from effective cost ratio control, the company raised its full-year adjusted EPS guidance from "at least $9.00" to "at least $9.50."
  • In One Sentence: Humana Inc. (HUM) leveraged strong execution to deliver better-than-estimated medical cost control and raised its member-weighted STARS rating for Bonus Year 2028 to a historical high of 4.17, with the stock rising 5.33% on the first trading day after earnings.

Quarterly Highlights

BY28 STARS rating hits record high, far exceeding top-quartile targets and providing a one-time tailwind for 2028. The most significant milestone this quarter was the result of the STARS ratings for Bonus Year 2028 (BY28), where the member-weighted STARS rating reached 4.17. This is one of the highest levels in Humana's history, significantly surpassing the company's "top quartile" goal. CEO Jim Rechtin stated that this represents the collective effort of 65,000 employees and will provide a one-time financial tailwind in 2028, a portion of which will be used for reinvestment and a portion returned to shareholders.

  1. Full-year adjusted EPS guidance raised, cost trends better than expected: CFO Celeste Mellet announced an increase in full-year adjusted EPS guidance from "at least $9.00" to "at least $9.50." The driver is medical cost trends landing at the low end of the 7%–8% range, with inpatient admissions per thousand (APTs) and cost per admission both performing better than expected, alongside additional favorability in Part D (pharmacy benefit) costs.

  2. BY28 STARS rating far exceeds top-quartile target, clinical outcomes are concrete and quantifiable: The member-weighted STARS rating of 4.17 significantly exceeds the company's top-quartile threshold. During the quarter, 663,000 more care opportunities were completed compared to the previous year, 534,000 members completed annual preventive visits, and 600 cases of previously undetected breast cancer and 100 cases of colorectal precancer or cancer were identified, demonstrating the material impact of clinical quality improvement.

  3. 2027 Annual Election Period (AEP) ahead of schedule, 2027 membership expected to grow year-over-year: CEO Jim Rechtin noted that AEP performance is currently exceeding initial expectations, with particularly strong retention among members affected by plan exits and new sales tracking ahead of plan. Management now expects individual Medicare Advantage (MA) membership in 2027 to grow compared to 2026, primarily driven by strengthened brokerage partnerships.

  4. New Joint Venture with BlackRock significantly improves balance sheet efficiency: Humana closed a new Joint Venture with BlackRock, replacing the previous long-term arrangement with Welsh Carson. This is expected to reduce the GAAP debt-to-cap ratio by approximately 130 basis points in 2026 Q4. Furthermore, the put option obligation originally due in 2027 has been eliminated; if fulfilled through debt, that obligation would have added an additional 130 basis points to the debt-to-cap ratio.

  5. Gentiva minority stake sale expected to bring approximately $900M pre-tax gain: Humana expects to complete the sale of its minority stake in Gentiva this quarter, with a pre-tax gain of approximately $900M, consistent with previous guidance. This capital will help strengthen the balance sheet and provide flexibility for subsequent capital allocation.

  6. Medicaid footprint continues to expand, adding 104,000 members in 2026: The Medicaid business added 104,000 members in 2026, primarily from the launch of Michigan HIDE-SNP, Illinois statewide FIDE-SNP programs, and the inclusion of dual eligibles in South Carolina. The Medicaid business currently spans 13 states, with 11 already launched and contracts in Georgia and Texas awarded and awaiting implementation.

  7. CenterWell Primary Care grows 30% YoY, adding nearly 147,000 members: CenterWell Primary Care added nearly 147,000 members in 2026, a year-over-year growth rate of approximately 30%, which includes the contribution from the MaxHealth acquisition completed in the first quarter. Management views this business as a vital strategic pillar for enhancing Medicare Advantage quality, driving STARS ratings, and managing overall medical costs.

  8. BY29 STARS quality improvement progress leading year-over-year, up approximately 5%: On key HEDIS metrics for BY29 STARS, the rate of quality improvement per member was approximately 5% higher than the same period last year as of the end of the third quarter. Management expressed confidence in achieving the BY29 top-quartile target.

Sign up for free!

You can sign up for free or Log In to read more information!

Free In-Depth for popular US stocks:

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer